Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.

Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.